Zai Operating Margin from 2010 to 2026
| ZLAB Stock | USD 16.30 0.30 1.81% |
Check Zai Lab financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zai Lab's main balance sheet or income statement drivers, such as Depreciation And Amortization of 24.5 M, Interest Expense of 4.3 M or Selling General Administrative of 360.7 M, as well as many indicators such as Price To Sales Ratio of 7.29, Dividend Yield of 0.0 or PTB Ratio of 2.99. Zai financial statements analysis is a perfect complement when working with Zai Lab Valuation or Volatility modules.
Zai | Operating Margin | Build AI portfolio with Zai Stock |
Analyzing Zai Lab's Operating Margin over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Margin has evolved provides context for assessing Zai Lab's current valuation and future prospects.
Latest Zai Lab's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Zai Lab over the last few years. It is Zai Lab's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zai Lab's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.42) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Zai Operating Margin Regression Statistics
| Arithmetic Mean | (581.66) | |
| Coefficient Of Variation | (96.52) | |
| Mean Deviation | 543.69 | |
| Median | (1,095) | |
| Standard Deviation | 561.40 | |
| Sample Variance | 315,172 | |
| Range | 1.1K | |
| R-Value | 0.87 | |
| Mean Square Error | 83,121 | |
| R-Squared | 0.75 | |
| Slope | 96.46 | |
| Total Sum of Squares | 5M |
Zai Operating Margin History
About Zai Lab Financial Statements
Zai Lab stakeholders use historical fundamental indicators, such as Zai Lab's Operating Margin, to determine how well the company is positioned to perform in the future. Although Zai Lab investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zai Lab's assets and liabilities are reflected in the revenues and expenses on Zai Lab's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zai Lab. Please read more on our technical analysis and fundamental analysis pages.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. Zai Lab operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1951 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock:Check out the analysis of Zai Lab Correlation against competitors. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. Anticipated expansion of Zai directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zai Lab assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.90) | Revenue Per Share | Quarterly Revenue Growth 0.135 | Return On Assets | Return On Equity |
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Zai Lab's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.